What is a stock summary page? Click here for an overview.
Business Description
Abingdon Health PLC
ISIN : GB00BLF79J41
Description
Abingdon Health PLC is a technology-enabled lateral flow diagnostics company. It provides rapid testing solutions to clients in healthcare and other industries. The firm's product ABC-19 is an antibody test for Covid-19 , and also produces tests covering areas such as self-test HIV, equine infection, human fertility, etc. Business operating segments includes; Contract Development comprises development work for third parties; Contract Manufacturing comprises contract development and manufacturing activities; Regulatory Services; and Product Sales comprises the sale of ABC-19, Pocket Diagnostic products, PCRD tests and antibodies for research use. Key revenue comes from Contract Development segment. Geographically it operates in the UK, USA and Canada, Europe and the rest of the world.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.64 | |||||
| Equity-to-Asset | 0.65 | |||||
| Debt-to-Equity | 0.16 | |||||
| Debt-to-EBITDA | -0.43 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -4.57 | |||||
| Beneish M-Score | 0.73 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -23.1 | |||||
| 3-Year EBITDA Growth Rate | 49.3 | |||||
| 3-Year EPS without NRI Growth Rate | 32.5 | |||||
| 3-Year FCF Growth Rate | 57.3 | |||||
| 3-Year Book Growth Rate | -56.7 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 36.02 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 26.99 | |||||
| 9-Day RSI | 28.87 | |||||
| 14-Day RSI | 30.19 | |||||
| 3-1 Month Momentum % | -6.45 | |||||
| 6-1 Month Momentum % | -21.62 | |||||
| 12-1 Month Momentum % | -21.62 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.55 | |||||
| Quick Ratio | 2.36 | |||||
| Cash Ratio | 1.51 | |||||
| Days Inventory | 48.76 | |||||
| Days Sales Outstanding | 65.34 | |||||
| Days Payable | 184.68 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -9.7 | |||||
| Shareholder Yield % | -45.79 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 52.57 | |||||
| Operating Margin % | -36.35 | |||||
| Net Margin % | -37.94 | |||||
| FCF Margin % | -39.32 | |||||
| ROE % | -74.03 | |||||
| ROA % | -39.33 | |||||
| ROIC % | -87.15 | |||||
| 3-Year ROIIC % | -18.31 | |||||
| ROC (Joel Greenblatt) % | -277.02 | |||||
| ROCE % | -61.61 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 16.25 | |||||
| PS Ratio | 3.1 | |||||
| PB Ratio | 1.91 | |||||
| Price-to-Tangible-Book | 3.25 | |||||
| EV-to-EBIT | -3.51 | |||||
| EV-to-Forward-EBIT | -19.31 | |||||
| EV-to-EBITDA | -4.13 | |||||
| EV-to-Forward-EBITDA | -1931.4 | |||||
| EV-to-Revenue | 1.42 | |||||
| EV-to-Forward-Revenue | 0.77 | |||||
| EV-to-FCF | -3.6 | |||||
| Price-to-GF-Value | 0.54 | |||||
| Price-to-Net-Current-Asset-Value | 6.5 | |||||
| Earnings Yield (Greenblatt) % | -28.49 | |||||
| FCF Yield % | -21.76 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Abingdon Health PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil £) | 6.819 | ||
| EPS (TTM) (£) | -0.007 | ||
| Beta | -0.7 | ||
| 3-Year Sharpe Ratio | -0.05 | ||
| 3-Year Sortino Ratio | -0.08 | ||
| Volatility % | 29.62 | ||
| 14-Day RSI | 30.19 | ||
| 14-Day ATR (£) | 0.005193 | ||
| 20-Day SMA (£) | 0.06821 | ||
| 12-1 Month Momentum % | -21.62 | ||
| 52-Week Range (£) | 0.06 - 0.1175 | ||
| Shares Outstanding (Mil) | 189.52 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Abingdon Health PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Abingdon Health PLC Stock Events
| Event | Date | Price (£) | ||
|---|---|---|---|---|
| No Event Data | ||||
Abingdon Health PLC Frequently Asked Questions
What is Abingdon Health PLC(LSE:ABDX)'s stock price today?
The current price of LSE:ABDX is £0.07. The 52 week high of LSE:ABDX is £0.12 and 52 week low is £0.06.
When is next earnings date of Abingdon Health PLC(LSE:ABDX)?
The next earnings date of Abingdon Health PLC(LSE:ABDX) is 2025-10-08 Est..
Does Abingdon Health PLC(LSE:ABDX) pay dividends? If so, how much?
Abingdon Health PLC(LSE:ABDX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers